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effectiveness ratio (ICER). Bootstrapping technique was applied for assessing
uncertainty in cost-effectiveness analyses. The robustness of findings was tested
in sensitivity analyses. RESULTS:Although there were no significant differences in
medication adherence and hospitalization outcomes between two groups, patients
in CR programs had a gradually improved medication adherence and lower hospi-
talization over time. Mean annual costs (2003 value) were $3172 and $2092 per
patient for CR group and control group, respectively. The ICER was $538 for 1%
improvement inmedication adherence and $1080 for an additional hospitalization
avoided. CONCLUSIONS: CR programs offered benefits of improving medication
adherence and reducing hospitalization over time although it was costly in the
beginning of its provision. Trade-off of increase in costs for the increase in benefits
should be considered.
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OBJECTIVES: To analyze the cost-effectiveness of treating hypertensive patients
with azilsartan medoxomil and chlorthalidone fixed dose combination (AZL-M/
CLD FDC) therapy compared with other angiotensin receptor blocker (ARB) and
hydrochlorothiazide (HCT) combinations commonly available in the US market.
METHODS:AMarkov Cohort Simulation approachwas utilized. Simulated patients
start in a hypertensive state and are followed over multiple time periods as they
transition betweenmutually exclusive health states. Cost per Quality Adjusted Life
Year (Cost/QALY) and Incremental Cost-effectiveness Ratios (ICERs) are calculated
over all possible dose combinations. Cardiovascular disease (CVD) riskswere based
on the Framingham risk equations. FDCs of HCT and eight ARBs commonly used in
the US market (Atacand HCT, Avalide, Benicar HCT, Hyzaar, Diovan HCT, generic
Losartan HCT, Micardis HCT and Teveten HCT) were included in the analyses.
RESULTS: Results suggest that AZL-M/CLD FDC is less expensive and more effec-
tive in lowering BP versus all branded ARB/HCT FDC comparators. When consider-
ing average costs and the CVD risks based on the Framingham risk equations for all
therapies over a five year time horizon, AZL-M/CLD FDC would remain the least
expensive andmost effective branded ARB/Diuretic FDC therapy up to a 23.5% unit
cost increase with the average office SBP reduction of -22.3% and up to 18.1% unit
cost increase with the 24-hour ambulatory BP reduction of -17.0%. CONCLUSIONS:
AZL-M/CLD FDC is predicted to be less expensive and more effective in reducing
blood pressure and cardiovascular risk when compared to all branded ARB/HCT
FDC comparators during a five year time horizon.
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OBJECTIVES: To estimate the cost-effectiveness of Dabigatran compared to War-
farin in non-complicated atrial fibrillation in Colombia.METHODS:We developed
a Markov model to represent the health states of atrial fibrillation and its compli-
cations;6 health states and 2 transitional states were considered,including dis-
abling and non-disabling stroke, myocardial infarction, pulmonary embolism and
death. Major andminor hemorrage were considered transitory in the model. Prob-
abilities were derived from published clinical trials. Resource use was estimated
from the Colombian Society of Cardiology guidelines and validated to adjust to
usual practice. Directmedical costswere derived fromdifferent sources (public and
private) and indirect costs (predicted wages lost and transportation costs) were
obtained from the most recent National Health Survey. Utilities were obtained
from a systematic literature review. Two separate analysis, payer and societal
perspective, were performed in a 20-year horizon. Maximum andminimum values
of effectiveness and resource use were included in the sensitivity analysis. The
results were discounted at 3% annually. RESULTS: After 20 years of follow up,
discounted direct medical costs accounted for USD$70,500 for Warfarin and
$78,840 and $79,860 for 150mg and 110mg of Dabigatran, respectively.When taking
into account indirect costs,Warfarin increased their costs by 13%while Dabigatran
costs were increased by 9%. Estimated life years for Dabigatran were higher (9.40
and 9.29 for 150mg and 110mg, respectively) as well as the QALYs (8.48, 8.39) than
for Warfarin 9.09 LY and 8.12 QALYs. The calculated ICER was $23,760 and $34,690
per additional QALY when taking into account direct costs and even lower when
considering indirect costs. CONCLUSIONS: In Colombia, the use of Dabigatran for
the management of non-complicated atrial fibrilation compared to Warfarin in-
creases years of life and QALYs. Assuming a similar willingnes-to-pay as for other
cardiovascular interventions, dabigatran is a cost-effective intervention.
PCV52
URAPIDIL IN TREATMENT OF HYPERTENSION URGENCIES IN THE RUSSIAN
FEDERATION: COST-EFFECTIVENESS ANALYSIS
Kulikov A, Protsenko M, Misikova B
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
OBJECTIVES: To assess the cost-effectiveness of urapidil compared with standard
treatment of hypertension urgenciesMETHODS: A decision tree was used to sim-
ulate the effects of urapitil and standard therapy drugs such as captopril, clonidine,
nifedipine, metoprolol, magnesium sulphate, furosemide, enalaprilat. Standard
therapy drugs were revealed after observational study of prehospital treatment of
hypertension crisis. The efficacy of drugs was obtained from clinical trials, while
medical care costs were estimated from standard of treatment of hypertension
urgencies developed and published by Ministry of public health. A cost-effective-
ness ratio of urapidil was compared with other drugs. At the last stage double
phase sensitivity analysis was conducted. RESULTS: A CER of urapidil was the
lowest (1942.89 RUB/64.73$) in comparison to another drugs (captopril-1966.34
RUB/65.53$; metoprolol-2191.43 RUB/73.03$; enalaprilat - 2443.52 RUB/81.45$; ni-
fedipine-2485.71 RUB/82.83$; furosemide-2505.53 RUB/83.5$; clonidine-2558.12
RUB/85.26$; ; magnesium sulphate -2932.92 RUB/97.73$). Sensitivity analysis dem-
onstrated stability of results, changing cost of hospitalization and cost of urapidil
the advantage of urapidil from the position of “cost-effectiveness” was still
obviously. CONCLUSIONS: Treatment of hypertension urgencies with urapidil is a
dominated alternative from the perspective of the health economics.
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OBJECTIVES: To compare the costs and effectiveness of dabigatran etexilate with
current standard treatment in patients with non-valvular atrial fibrillation (NVAF),
from the Slovakian health care system perspective. METHODS: A previously pub-
lishedMarkov cohortmodelwas adopted to estimate the outcomes of patientswith
dabigatran (150mg BID, 110mg BID) in its labelled indication during their lifetime
for the following health states: ischemic and haemorrhagic stroke, transient isch-
emic attack, systemic embolism, intracranial and extracranial haemorrhage, acute
myocardial infarction, minor bleeds and death. Data on event rates and patient
quality of life associated with different health states and patient survival time was
based on the RE-LY trial and the literature. The base-case consisted of a cohort of
patients with NVAF, CHADS21 and no contraindications to anticoagulation ther-
apy. Themodelled consequences of the clinical eventswere costs, disability and/or
reduction in quality of life and death. Data on resource use associated with patient
management and different events were estimated using a Slovakian expert panel,
while unit prices were collected from the official sources update 2011. One-way
sensitivity analyses was used on all relevant variables to test the robustness of the
analysis. RESULTS: The dabigatran group had more life years and QALYs gained
compared to standard treatment (warfarin, aspirin, clopidogrel and no treatment);
these gains were primarily driven by a lower incidence of the intracranial events
and systemic embolism. A cohort of 5,000 patients treated with dabigatran during
their lifetime gained 40,238QALYs (standard: 38,178QALYs)with incremental costs
of €35.9mill (standard: €37.3mill). The incremental cost-effectiveness ratio (ICER) of
dabigatran versus standard treatment was estimated at €17,437, below the Slovak-
ian acceptable threshold (€18,000 per QALY gained). The sensitivity analysis con-
sistently demonstrated the cost-effectiveness of dabigatran. CONCLUSIONS: Dab-
igatran represents a cost-effective treatment for preventing strokes in patients
with NVAF in Slovakia.
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OBJECTIVES: Dabigatran was approved in the United States to reduce the risk of
stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF).
Dabigatran has several potential advantages over the current standard of care
(warfarin), including a generally better side effect profile, fewer drug interactions,
and no international normalized ratio (INR)monitoring, but it is considerablymore
expensive. The objective of this analysis was to determine the cost-effectiveness of
dabigatran versus warfarin for AF in a Medicare population.METHODS: A Markov
model was used to simulate outcomes for patients aged 65 with AF and a (CHADS2)
congestive heart failure, hypertension, age, diabetes, prior stroke [doubled] score
1. A 5-year time horizon and a managed care perspective were employed in this
analysis. Data comparing the clinical performance of dabigatran and warfarin was
derived from the RE-LY trial. Quality-adjusted life-years (QALYs) were used to as-
sess outcomes and utility weights were obtained from systematic reviews. Direct
medical costs associated with complications from AF were based on hospitaliza-
tion costs for diagnostic-related groups and reported in U.S. 2011 dollars. RESULTS:
Over a 5-year period, the incremental cost-effectiveness ratio (ICER) for dabigatran
150 mg was $26,551 per QALY compared to warfarin. The ICER was most sensitive
to the utility associatedwith thewell state for each of the alternatives aswell as the
price of dabigatran, warfarin, and INR monitoring needed for warfarin therapy. In
probabilistic analyses, dabigatran was cost-effective in 91% of simulations at a
$50,000/QALY threshold. CONCLUSIONS: Prescribing dabigatran increases quality-
adjusted life expectancy for AF patients at a cost considered acceptable by Amer-
ican payers.
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